#Immunic
Immunic, Inc. Unveils Q3 2026 Performance and Milestones for Neurological Drug Development#USA#New_York#Multiple_Sclerosis#Immunic#Vidofludimus
Immunic, Inc. Unveils Q3 2026 Performance and Milestones for Neurological Drug Development
Immunic, Inc. announces its Q3 2026 financial results, highlighting progress in multiple sclerosis trials and leadership appointments, with significant developments ahead.
third-news.com
November 13, 2026 at 11:46 AM
November 9, 2026 at 2:15 PM
$IMUX — Press Release

Immunic, Inc. (Nasdaq: IMUX) furnished under Regulation FD a presentation for its Progressive Multiple Sclerosis (PMS) Research and Development Day webinar held November 5, 2026 from 12:30 to 2:00 p.m.

🧵 continued ↓
November 5, 2026 at 10:01 PM
🚨 $IMUX
On November 5, 2026, Immunic, Inc. is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar . The PMS R&D Day will take place on Thursday, November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET via video conference.
SEC Filing: IMUX
Click to view the official SEC document.
www.sec.gov
November 5, 2026 at 2:03 PM
Immunic ($IMUX) – 13G holder adds

• Holder: Aberdeen
• Stake: 6.05% → 7.99% (about $8M)
• Shares: 824,393 → 1,090,427
• Filed: Nov 2 · Schedule 13G/A

📊 Track ownership filings at www.elixstocks.com

Educational purposes only. Not investment advice.

#Investing #Stocks #13G #ElixStocks
Aberdeen Group plc: 7.99% of Immunic ($IMUX)
Schedule 13G/A filed Nov 2. Who filed, the stake, and how it changed.
elixstocks.com
November 2, 2026 at 1:49 PM
#$IMUX virtual progressive MS R&D Day: Thu Nov 5, 12:30 p.m. ET. Close $7.80 (Oct 29), RSI 43, 20d range $6.35-$8.87.
imux.com/immunic-to-h...
www.merlintrader.com/immunic-stoc...
October 30, 2026 at 3:04 PM
#$IMUX weekly close $7.51 (+1.3% w/w), below SMA50 $10.25 / below SMA200 $11.50, RSI 40.3. Support $6.35, resistance $8.60. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/immunic-stoc...
October 31, 2026 at 6:22 AM
#$IMUX weekly close $7.51 (+1.3% w/w), below SMA50 $10.25 / below SMA200 $11.50, RSI 40.3. Support $6.35, resistance $8.60. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/immunic-stoc...
October 31, 2026 at 6:22 AM
#$IMUX virtual progressive MS R&D Day: Thu Nov 5, 12:30 p.m. ET. Close $7.80 (Oct 29), RSI 43, 20d range $6.35-$8.87.
imux.com/immunic-to-h...
www.merlintrader.com/immunic-stoc...
October 30, 2026 at 3:04 PM
Immunic to Host an Innovative R&D Day on Progressive MS in November 2026#United_States#New_York#Immunic#Vidofludimus#MS
Immunic to Host an Innovative R&D Day on Progressive MS in November 2026
Immunic, Inc. will conduct a virtual R&D Day focused on progressive multiple sclerosis on November 5, 2026, featuring expert insights and research updates.
third-news.com
October 29, 2026 at 11:08 AM
🙋Ahoj všem!!!
Za RP a ❤️děkuji!!!
#roztrousenenoviny📰

Dlouhodobá naděje pro progresivní RS: Včasné nasazení tablety vidofludimus vápenatý mírní invaliditu a tlumí buňky viru mononukleózy

Více:⬇️
www.roztrouseni.cz/dlouhodoba-n...
Dlouhodobá naděje pro progresivní RS: Včasné nasazení tablety vidofludimus vápenatý mírní invaliditu a tlumí buňky viru mononukleózy
Přestože vývoj léků pro progresivní formy roztroušené sklerózy (RS) naráží na řadu překážek, nová data přinášejí velkou porci optimismu. Společnost Immunic představila na nedávném mezinárodním neurolo...
www.roztrouseni.cz
October 28, 2026 at 3:03 PM
$IMUX Latest company news, Oct 21, 2026: at MSToronto 2026, CALLIPER open-label extension data for vidofludimus calcium supported the durability of disability outcomes. Exploratory analyses.

https://www.merlintrader.com/immunic-stock-hub/
Immunic $IMUX: Vidofludimus, ENSURE And Cash
Immunic’s vidofludimus calcium program explained: ENSURE, CALLIPER, scientific evidence, cash runway, warrants and the next MS catalysts.
www.merlintrader.com
October 21, 2026 at 4:40 PM
#IMUX Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSTo…

https://www.stocktitan.net/news/IMUX/immunic-presents-new-clinical-biomarker-and-preclinical-data-for-mx1w9ep9v2nn.html?utm_source=stocktitan-bluesky&utm_medium=social
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic (IMUX) is presenting new clinical, biomarker and preclinical findings for investigational vidofludimus calcium in four posters at MSToronto2026.Phase 2 CALLIPER extension analyses showed maintained favorable disability trends among patients continuing treatment; 6.5% discontinued through January 27, 2026. Exploratory analyses found reduced Epstein-Barr virus-specific immune signatures, with reductions associated with improved processing-speed scores. Post-hoc disability analyses favored treatment over placebo, while preclinical findings suggested neuronal protection requiring Nurr1, a protein involved in gene regulation. CALLIPER did not meet its primary brain-volume endpoint.Immunic expects to initiate Phase 3 testing in progressive multiple sclerosis later in 2026 and report top-line results from its fully enrolled Phase 3 ENSURE trials in relapsing multiple sclerosis by year-end 2026.
www.stocktitan.net
October 21, 2026 at 11:00 AM
Latest company news, October 19, 2026: Immunic appointed Jaa Roberson as Chief People Officer, a newly created role, ahead of the pivotal Phase 3 ENSURE read-out expected by the end of 2026. $IMUX

https://www.merlintrader.com/immunic-stock-hub/
Immunic $IMUX: Vidofludimus, ENSURE And Cash
Immunic’s vidofludimus calcium program explained: ENSURE, CALLIPER, scientific evidence, cash runway, warrants and the next MS catalysts.
www.merlintrader.com
October 19, 2026 at 11:16 PM
Immunic Strengthens Leadership with Jaa Roberson's Appointment as Chief People Officer#USA#New_York#Immunic#IMU-838#Jaa_Roberson
Immunic Strengthens Leadership with Jaa Roberson's Appointment as Chief People Officer
Immunic, Inc. has announced the appointment of Jaa Roberson as Chief People Officer, enhancing its leadership in preparing for regulatory filings and commercialization efforts.
third-news.com
October 19, 2026 at 10:44 AM
Immunic #$IMUX: Vidofludimus, ENSURE And Cash

Free Biotech Catalyst Calendar on Merlintrader.

www.merlintrader.com/immunic-stoc...
October 18, 2026 at 6:44 AM